A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
Novo Nordisk details Irish expansion; EuroAPI’s challenges continue
Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
Novo Nordisk teams with Langer-founded biotech for oral obesity drugs
Novo Nordisk teams with Langer-founded biotech for oral obesity drugs
Novo Nordisk to slash Wegovy list price in half in 2027
Novo Nordisk to slash Wegovy list price in half in 2027
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Novo Nordisk to expand Irish factory for Wegovy pill
Novo Nordisk to expand Irish factory for Wegovy pill
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
Novo Nordisk eyes a strong launch with FDA approval of obesity pill
Novo Nordisk eyes a strong launch with FDA approval of obesity pill
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
Novo Nordisk hit with FDA warning letter over acquired Catalent factory
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page